Continuing the trend of big pharma divesting its non-core assets, Sanofi has agreed to sell its Dermik dermatology unit to Valeant Pharmaceuticals for approximately US$425 M in order to focus on its key growth platforms. Valeant’s growing dermatology business will benefit from Dermik’s significant presence in the medical dermatology market in the US and Canada and from its manufacturing facility, which will provide increased capacity for the company. Valeant will also gain access to Dermik’s key therapeutic and aesthetic dermatology brands.